Mostrar el registro sencillo del ítem

Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis

dc.contributor.authorVallejo C.
dc.contributor.authorMontesinos P.
dc.contributor.authorPolo M.
dc.contributor.authorCuevas B.
dc.contributor.authorMorado M.
dc.contributor.authorRosell A.
dc.contributor.authorXicoy B.
dc.contributor.authorDíez J.L.
dc.contributor.authorSalamero O.
dc.contributor.authorCedillo Á.
dc.contributor.authorMartínez P.
dc.contributor.authorRayón C.
dc.date.accessioned2020-09-02T22:29:55Z
dc.date.available2020-09-02T22:29:55Z
dc.date.issued2015
dc.identifier10.1007/s00277-015-2305-3
dc.identifier.citation94, 6, 947-954
dc.identifier.issn09395555
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6513
dc.descriptionStudies comparing rabbit antithymocyte globulin (rATG) and horse ATG (hATG) in patients with aplastic anemia (AA) have shown conflicting results. These studies included fewer than 60 subjects in the rATG arm with relatively short follow-up. A total of 169 patients treated with rATG and 62 treated with hATG were included in this retrospective analysis, across 33 centers. Patients were treated with rATG or hATG plus cyclosporine A. Over half were classified, as having severe AA (SAA) or very severe AA (VSAA), and the mean follow-up was 45 months. There was no significant difference detected in cumulative response to treatment or survival between the rATG and hATG groups. The response to treatment was 63 % in the rATG group versus 66 % in the hATG group at 3 months. By 12 months, this pattern had reversed, and 84 % of rATG patients had responded to treatment versus 76 % in the hATG group (n.s.). Early mortality due to infection tended to be higher with rATG compared to hATG (n.s). rATG and hATG would seem to be therapeutically equivalent in SAA and VSAA. However, patients treated with rATG may take longer to respond than those treated with hATG and may also require more active prevention of early infections. © 2015, Springer-Verlag Berlin Heidelberg.
dc.language.isoen
dc.publisherSpringer Verlag
dc.subjectAntibody therapy
dc.subjectAplastic anemia
dc.subjectClinical aspects
dc.subjectImmunotherapy
dc.subjectLate effects of therapy
dc.subjectlymphocyte antibody
dc.subjectadult
dc.subjectaged
dc.subjectAnemia, Aplastic
dc.subjectanimal
dc.subjectblood
dc.subjectcomparative study
dc.subjectfemale
dc.subjectfollow up
dc.subjecthorse
dc.subjecthuman
dc.subjectintravenous drug administration
dc.subjectmale
dc.subjectmiddle aged
dc.subjectrabbit
dc.subjectretrospective study
dc.subjectspecies difference
dc.subjecttreatment outcome
dc.subjectyoung adult
dc.subjectAdult
dc.subjectAged
dc.subjectAnemia, Aplastic
dc.subjectAnimals
dc.subjectAntilymphocyte Serum
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHorses
dc.subjectHumans
dc.subjectInfusions, Intravenous
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRabbits
dc.subjectRetrospective Studies
dc.subjectSpecies Specificity
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.titleRabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84937512197.pdf
Tamaño:
3.375Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem